AB
Active Biotech
Sweden - Lund
Biotechnology1 H-1B visas (FY2023)Focus: Small Molecules, Biologics
Active Biotech is a life sciences company focused on Small Molecules, Biologics.
OncologyImmunologyHematology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Laquinimod
Eye DiseasesClinical Trials (1)
NCT05187403A Study of Laquinimod Eye-drops in Healthy Participants
Phase 1ABR-217620
Non-Small-Cell Lung CarcinomaClinical Trials (1)
NCT00056537ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Phase 1Tasquinimod
Multiple MyelomaClinical Trials (1)
NCT04405167Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase 1ABR-217620
Carcinoma, Non-Small-Cell LungClinical Trials (1)
NCT00132379ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
Phase 1ABR-215050
HealthyClinical Trials (1)
NCT01048203A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects
Phase 1Ruxolitinib
Primary MyelofibrosisClinical Trials (1)
NCT06327100Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Phase 1/2Laboratory Biomarker Analysis
Hormone-Resistant Prostate CancerClinical Trials (1)
NCT02159950Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2paquinimod
Systemic Lupus ErythematosusClinical Trials (1)
NCT00997100Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
Phase 2ABR-215050, tasquinimod
Prostate CancerClinical Trials (1)
NCT00560482Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase 2paquinimod
Systemic SclerosisClinical Trials (1)
NCT01487551An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
Phase 2ABR-217620/naptumomab estafenatox
Renal Cell CarcinomaClinical Trials (1)
NCT00420888ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Phase 2/3tasquinimod
Prostate CancerClinical Trials (1)
NCT01234311A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 12 clinical trials
H-1B (2023): 1 approval
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub